A recent survey reveals that many Americans view weight-loss medications, such as Ozempic and Wegovy, positively for adults facing obesity or related health issues. However, there is less support for their use among teenagers dealing with obesity.
The poll, conducted by the Associated Press-NORC Center for Public Affairs Research, shows a split opinion on weight-loss drugs for young people aged 12 to 18. About one-third see their use as beneficial, while an equal number believe it is detrimental. The remaining respondents feel neutral about the topic. In contrast, roughly half of adults consider these medications a good option, while about 20% disagree.
These weight-loss drugs, known as GLP-1 receptor agonists, originally aimed to treat diabetes but gained attention as effective solutions for weight management after receiving FDA approval for this purpose in 2021. Their popularity has skyrocketed, featuring prominently in celebrity endorsements, commercials, and social media discussions.
Medical experts assert that these injectable drugs can be useful for combating obesity. The American Medical Association has urged insurance companies to provide coverage for these medications. Additionally, the American Academy of Pediatrics suggests that healthcare providers should consider offering these drugs to adolescents aged 12 and older who are struggling with obesity. Despite medical endorsements, some Americans remain skeptical, particularly about administering these medications to adolescents and individuals who are not clinically classified as obese.
According to the CDC, over 100 million adults in the United States are classified as obese, which is defined as having a body mass index (BMI) of 30 or higher. Obesity can stem from a mix of genetic, environmental, and socioeconomic factors, and it is recognized as a chronic disease requiring medical intervention. Critics may argue that those using weight-loss drugs are “cheating,” but proponents argue that these medications help level the playing field for those battling obesity.
People like Anjanette Ewen, who lost 67 pounds using Mounjaro and credits her weight loss for a cancer diagnosis, illustrate the potential benefits of these medications. She faced significant challenges due to a condition causing sudden weight fluctuations, highlighting the difficult realities many face.
The data shows that 20% of children in America are also affected by obesity. Medical professionals, such as Dr. Gitanjali Srivastava from Vanderbilt University, emphasize that treating obesity in children can yield positive results more easily than in adults. Early intervention is crucial, as childhood obesity often leads to more severe issues later in life.
Insurance coverage for these medications is a significant concern. The out-of-pocket costs for weight-loss drugs can be quite high, which often discourages many from seeking treatment. Approximately half of Americans support the idea of Medicare and Medicaid covering weight-loss medications for those classified as obese, while a smaller portion is against this idea.
However, Medicare currently does not cover these drugs for treating obesity, and Medicaid coverage varies widely. While some larger companies and Medicaid programs are beginning to include coverage, many employers and insurers are cutting back due to costs.
For adults and teens who are not medically classified as obese, a substantial number of Americans disapprove of using GLP-1 medications for weight loss, with around 60% believing it to be inappropriate for non-obese adults and even more—about 70%—for teens in the same situation. There appears to be a generational divide, with older adults more likely to oppose the idea than younger adults.
As the conversation around obesity treatment continues, it remains essential for both individuals and society to weigh the benefits and risks of medical interventions carefully.
